Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
Breast Cancer, Lung cancer, Pancreatic caner(cytotoxic chemotheraphy) More
A monoclonal antibody against GluR3B, a peptide found in epilepsy patients, and especially in patients suffering from intractable, resistant forms of the disease, could be used in diagnosis kits as well as in drug development for this form of "autoimmune. More
Lotuzol is a new herbal drug composing water extract powder of Nelumbinis Semen to treat depression without sexual dysfunction, a major adverse effect in commonly used anti-depressants. More
An in vitro hepatitis C virus (HCV) replication system that is capable of producing viral particles in a culture medium More
DNA-Based Therapeutic Angiogenesis / Protein Therapeutic for Thrombocytopenia / Therapeutic Cancer Vaccine Targeting HER2/neu / Hardy Kiwi Extract for Immune Hypersensitivity More
This technology is related to optimal conditions for culturing stem cells and feeder cells More
A DNA microarray that becomes a protein microarray on demand and provides an efficient systematic approach to the study of protein interactions and drug target identification and validation. More
A rapid and automated method for discovering potential drugs for the treatment of sickle cell anemia, using a combination of laser photolysis and statistical processing of digital images. More
Colorless molecule that will bind and enhance the differential surface charge on protein complexes: The molecule has been demonstrated to work as well as Coomassie blue but will not interfere in gel assays critical for most investigations. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Jan 2011 - 99 pages - $3,835
Aug 2010 - 80 pages - $1,215
Sep 2010 - 21 pages - $99
Aug 2010 - 138 pages - $1,215
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Apr 2011 - 24 pages - $500
Aug 2011 - 7 pages - $75
Dec 2010 - 27 pages - $500
May 2011 - 32 pages - $500
Your selection
- Industry sector
- Drug discovery del
Browse By
- Industry sector
- Bioinformatics
- Combinatorial biology
- Combinatorial chemistry
- Drug research platforms
- Genomics
- High throughput screening
- Proteomics
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us